Shire PLC (ADR)  

(Public, NASDAQ:SHPG)   Watch this stock  
Find more results for NASDAQ:SHPGY
+1.45 (0.56%)
Real-time:   3:27PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 256.40 - 259.70
52 week 156.25 - 264.98
Open 258.13
Vol / Avg. 362,057.00/572,564.00
Mkt cap 51.04B
P/E 14.84
Div/yield 0.57/0.26
EPS 17.50
Shares 600.20M
Beta 0.69
Inst. own 8%
Jul 23, 2015
Q2 2015 Shire PLC Earnings Release - 3:00AM EDT - Add to calendar
Jun 2, 2015
Shire PLC at Jefferies Global Healthcare Conference - 10:00AM EDT - Add to calendar
May 7, 2015
Shire PLC at Deutsche Bank Health Care Conference
Apr 30, 2015
Q1 2015 Shire PLC Earnings Call
Apr 30, 2015
Q1 2015 Shire PLC Earnings Release
Apr 28, 2015
Shire PLC Annual Shareholders Meeting
Mar 24, 2015
Shire PLC at Biotechnology Industry Organization (BIO) Asia International Conference
Mar 3, 2015
Shire PLC at Cowen Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin 27.81% 54.47%
Operating margin 31.89% 28.20%
EBITD margin - 43.82%
Return on average assets 10.60% 29.88%
Return on average equity 18.77% 46.80%
Employees 5,016 -
CDP Score - 91 B


5 Riverwalk Citywest Business Campus, Dublin 24
+353-1-4297700 (Phone)
+353-1-4297701 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Shire Plc is a specialty biopharmaceutical company that focuses on developing and marketing innovative specialty medicines that address unmet patient needs. The Company’s products included VYVANSE/VENVANSE (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), EQUASYM (methylphenidate hydrochloride) modified release (XL), LIALDA (mesalamine)/ MEZAVANT(mesalazine), PENTASA (mesalamine), RESOLOR (prucalopride), FOSRENOL (lanthanum carbonate), XAGRID (anagrelide hydrochloride), REPLAGAL (agalsidase alfa), ELAPRASE (idursulfase), VPRIV (velaglucerase alfa), FIRAZYR (icatibant) and DERMAGRAFT(Human Fibroblast-Derived Dermal Substitute), CINRYZE. The Company focuses its development resources on projects in a number of therapeutic areas, including Neuroscience, Rare Diseases, Ophthalmology, Hematology and GI, and focuses its early development projects on rare diseases.

Officers and directors

Flemming Ornskov M.D. Chief Executive Officer, Executive Director
Age: 57
Bio & Compensation  - Reuters
Jeffrey Poulton Chief Financial Officer, Director
Age: 47
Bio & Compensation  - Reuters
Ginger Gregory Chief Human Resource Officer
Bio & Compensation  - Reuters
Mark J. Enyedy Interim General Counsel, Head of Corporate Development
Age: 51
Bio & Compensation  - Reuters
Phil J. Vickers Head of Research and Development
Age: 55
Bio & Compensation  - Reuters
Susan Saltzbart Kilsby Non-Executive Chairman of the Board
Age: 56
Bio & Compensation  - Reuters
David J. Kappler Senior Independent Non-Executive Deputy Chairman of the Board
Age: 67
Bio & Compensation  - Reuters
Dominic Blakemore Non-Executive Independent Director
Age: 45
Bio & Compensation  - Reuters
William Burns Non-Executive Independent Director
Age: 67
Bio & Compensation  - Reuters
Steven H. Gillis Ph.D. Non-Executive Independent Director
Age: 63
Bio & Compensation  - Reuters